An interpretable nomogram with SHAP analysis predicts thrombotic failure of forearm arteriovenous fistulas

利用SHAP分析构建的可解释列线图能够预测前臂动静脉瘘的血栓形成失败

阅读:1

Abstract

OBJECTIVE: End-stage renal disease is an increasing global health problem. Arteriovenous fistula (AVF) thrombosis is a major cause of access failure in maintenance hemodialysis (MHD) patients. An interpretable nomogram, integrated with SHapley Additive exPlanations (SHAP) analysis is developed and validated for predicting thrombotic failure of forearm AVFs in MHD patients. METHODS: A single-center retrospective cohort study enrolled 302 MHD patients with dysfunctional forearm AVFs undergoing percutaneous transluminal angioplasty. Patients were randomly allocated to training (70%) and validation (30%) sets. Univariable and multivariable logistic regression identified independent predictors for AVF thrombosis. A nomogram was constructed and its performance evaluated by the area under the receiver operating characteristic curve, calibration, and decision curve analysis. SHAP analysis was applied to quantify feature importance and directionality in the validation set. RESULTS: The final model identified hypertension history, frequent intradialytic hypotension, body mass index, total cholesterol, C-reactive protein, and intact parathyroid hormone as independent predictors. The nomogram demonstrated good discrimination, with AUCs of 0.80 (95% CI: 0.73-0.86) in the training set and 0.71 (95% CI: 0.59-0.83) in the validation set, along with satisfactory calibration and clinical utility. SHAP analysis revealed red cell distribution width-standard deviation as the most influential predictor for individual risk, highlighting a distinction between statistical significance and predictive contribution. CONCLUSION: This study presents an interpretable nomogram with robust performance for predicting AVF thrombosis. The integration of SHAP analysis enhances model transparency and clinical trust, providing a valuable tool for personalized risk assessment and potential targeting of preventive strategies in MHD patients. Further external validation is warranted.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。